OTC · CIK 0001137883
BCLI BRAINSTORM CELL THERAPEUTICS INC.
Insider trading from SEC Form 4. Last filing May 29, 2026.
Last 90 days
Net insider value
$0
no open-market trades
Buys
0
$0 by 0 insiders
Sells
0
$0 by 0 insiders
Insiders on file
11
with a Form 4 at this company
Signals
Open-market buys and sells at BRAINSTORM CELL THERAPEUTICS INC., scored.
No scored open-market trades yet. Grants, exercises and other rows are below.
Transactions
The last 23 rows filed, every code.
| Date | Insider | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|---|
| Feb 26, 2026 | Jacob A Frenkel director | AGrant or award Common Stock | +200,000 | $0.00 | $0 | 243,777 | May 29, 2026 |
| Feb 26, 2026 | Alla Patlis See Remarks | AGrant or award Common Stock | +100,000 | $0.00 | $0 | 144,349 | May 29, 2026 |
| Feb 26, 2026 | Uri Yablonka EVP & Chief Business Officer | AGrant or award Common Stock | +150,000 | $0.00 | $0 | 218,464 | May 29, 2026 |
| Feb 26, 2026 | Chaim Lebovits President & CEO | AGrant or award Common Stock | +1,800,000 | $0.00 | $0 | 2,000,960 | May 29, 2026 |
| Feb 26, 2026 | Irit Arbel director | AGrant or award Common Stock | +120,000 | $0.00 | $0 | 161,054 | May 29, 2026 |
| Feb 26, 2026 | Ibrahim B. Dagher Chief Medical Officer | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.70 | $158k | 225,000 | May 20, 2026 |
| Feb 26, 2026 | Nir Naor director | AGrant or award Stock Option (Right to Buy)derivative | +180,000 | $0.70 | $126k | 180,000 | May 20, 2026 |
| Feb 26, 2026 | Stacy Lindborg director | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.70 | $105k | 150,000 | May 20, 2026 |
| Feb 26, 2026 | Hartoun Hartounian EVP, Chief Operating Officer | AGrant or award Stock Option (Right to Buy)derivative | +225,000 | $0.70 | $158k | 225,000 | May 20, 2026 |
| Feb 26, 2026 | Anthony J. Polverino director | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.70 | $105k | 150,000 | May 20, 2026 |
| Feb 26, 2026 | Menghisteab Bairu director | AGrant or award Stock Option (Right to Buy)derivative | +150,000 | $0.70 | $105k | 150,000 | May 20, 2026 |
| Jan 1, 2025 | Ibrahim B. Dagher Chief Medical Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 66,849 | Jan 7, 2025 |
| Jan 1, 2025 | Menghisteab Bairu director | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 24,000 | Jan 3, 2025 |
| Jan 1, 2025 | Hartoun Hartounian EVP, Chief Operating Officer | AGrant or award Common Stock | +50,000 | $0.00 | $0 | 52,000 | Jan 3, 2025 |
| Jan 1, 2025 | Stacy Lindborg director | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 48,229 | Jan 3, 2025 |
| Jan 1, 2025 | Nir Naor director | AGrant or award Common Stock | +30,666 | $0.00 | $0 | 31,465 | Jan 3, 2025 |
| Jan 1, 2025 | Alla Patlis See Remarks | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 44,349 | Jan 3, 2025 |
| Jan 1, 2025 | Uri Yablonka EVP & Chief Business Officer | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 48,464 | Jan 3, 2025 |
| Jan 1, 2025 | Anthony J. Polverino director | AGrant or award Common Stock | +24,000 | $0.00 | $0 | 25,730 | Jan 3, 2025 |
| Jan 1, 2025 | Jacob A Frenkel director | AGrant or award Common Stock | +40,000 | $0.00 | $0 | 43,777 | Jan 3, 2025 |
| Jan 1, 2025 | Chaim Lebovits President & CEO | AGrant or award Common Stock | +120,000 | $0.00 | $0 | 200,960 | Jan 3, 2025 |
| Jan 1, 2025 | Irit Arbel director | AGrant or award Common Stock | +30,666 | $0.00 | $0 | 41,054 | Jan 3, 2025 |
| Jan 1, 2025 | Uri Yablonka EVP & Chief Business Officer | AGrant or award Common Stock | +20,000 | $0.00 | $0 | 68,464 | Jan 3, 2025 |
Insiders
Everyone who has filed a Form 4 here.
- Irit Arbeldirector
- Menghisteab Bairudirector
- Ibrahim B. DagherChief Medical Officer
- Jacob A Frenkeldirector
- Hartoun HartounianEVP, Chief Operating Officer
- Chaim LebovitsPresident & CEO
- Stacy Lindborgceo, president, officer, director
- Nir Naorcfo, officer, director
- Alla PatlisSee Remarks
- Anthony J. Polverinodirector
- Uri YablonkaEVP & Chief Business Officer
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.